哮喘生物制剂依从性:对患者选择、阶梯治疗和结局的影响
本研究基于OptumLab数据库分析5319例起始哮喘生物制剂的患者,发现生物制剂前6个月平均PDC为0.76,高于ICS前6个月的0.44和后6个月的0.40。生物制剂前ICS PDC≥0.75与生物制剂PDC≥0.75(OR 1.25)及生物制剂使用后ICS PDC≥0.75(OR 9.93)相关。ICS或生物制剂PDC≥0.75与哮喘急性发作显著减少无关。
要点
- 哮喘患者对生物制剂的依从性高于对ICS的依从性。
- 生物制剂前ICS依从性高与后续生物制剂依从性高相关。
- 生物制剂或ICS高依从性未显著减少哮喘急性发作。
核心结论
- 哮喘生物制剂依从性高于ICS依从性,且与不同因素相关。
研究设计与样本
- 分析OptumLab Data Warehouse中起始哮喘生物制剂的患者,数据截至2019年10月,共纳入5319人。
主要发现
- 生物制剂起始后前6个月平均PDC为0.76(95%CI 0.75-0.77),高于ICS起始前6个月的0.44(95%CI 0.43-0.45)和起始后6个月的0.40(95%CI 0.39-0.40)。
- 生物制剂使用前6个月ICS PDC≥0.75与生物制剂PDC≥0.75相关(OR 1.25;95%CI 1.10-1.43)。
- 生物制剂使用前6个月ICS PDC≥0.75与生物制剂使用后6个月ICS PDC≥0.75相关(OR 9.93;95%CI 8.55-11.53)。
- 在生物制剂使用前6个月有急性发作的患者中,ICS PDC≥0.75(OR 0.92;95%CI 0.74-1.14)或生物制剂PDC≥0.75(OR 1.15;95%CI 0.97-1.36)与生物制剂使用后前6个月哮喘急性发作减少≥50%无统计学显著关联。
临床怎么用
- 评估哮喘患者生物制剂治疗时,应关注既往ICS依从性,因其与生物制剂依从性相关。
- 生物制剂治疗期间仍需监测并提高ICS依从性。
- 生物制剂依从性高未必显著减少急性发作,需综合评估疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about adherence to asthma biologics. RESEARCH QUESTION: Is adherence to inhaled corticosteroid (ICS) associated with subsequent asthma biologic adherence? STUDY DESIGN AND METHODS: We analyzed individuals with asthma who started asthma biologics in the OptumLab Data Warehouse and used that data until October 2019. We calculated proportion days covered (PDC) for ICS ± long-acting β-agonists in the 6 months before and after asthma biologics were started and asthma biologic PDC for the first 6 months of use. We performed a multivariable analysis to identify factors associated with asthma biologic PDC ≥0.75, ICS PDC ≥0.75 during the 6-month period after asthma biologic were started, and achievement of a ≥50% reduction in asthma exacerbations during the first 6 months of asthma biologic use. RESULTS: We identified 5,319 people who started asthma biologics. The mean PDC for asthma biologics was 0.76 (95% CI, 0.75-0.77) in the first 6 months after starting, higher than the mean PDCs for ICS in the 6 months before (0.44 [95% CI, 0.43-0.45]) and after (0.40 [95% CI, 0.39-0.40]) starting the asthma biologic. PDC ≥0.75 for ICS 6 months before index biologic use is associated with PDC for asthma biologics ≥0.75 (OR, 1.25; 95% CI, 1.10-1.43) and for ICS during the first 6 months of biologic use (OR, 9.93; 95% CI, 8.55-11.53). Neither ICS PDC ≥0.75 (OR, 0.92; 95% CI, 0.74-1.14) nor asthma biologic PDC ≥0.75 (OR, 1.15; 95% CI, 0.97-1.36) is associated with a statistically significant reduction in asthma exacerbations during the first 6 months of asthma biologic use among people with any exacerbation in the 6 months before first use. INTERPRETATION: Adherence to asthma biologic is higher than to ICS and is associated with different factors.
引用
- Maddux JT, Inselman JW, Jeffery MM, et al. Adherence to Asthma Biologics: Implications for Patient Selection, Step Therapy, and Outcomes. Chest. 2020. PMID: 33558205. doi:10.1016/j.chest.2020.10.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。